 |
|
Bristol-Myers Squibb Process Research
and Development Laboratory rendering
|
Bristol-Myers Squibb is a world leader in providing life-saving
and life-extending therapies for patients with cancer. Respected
as one of the worlds most productive and innovative research organizations,
Bristol-Myers was in need of a new 150,000 sq. ft. Process Research
and Development Facility on their New Brunswick Campus. Included
in the scope of the new facility were three laboratory floors above
a ground-level entry floor and a BSL-3 (containment and hydrogenation).
Key client success factors were achieved by our ability to understand
and relay Bristol-Myers culture to the entire design team and our
ability to keep the project on schedule, saving an estimated $100
thousand dollars that could have resulted from change orders. Based
on our experience with BMS’s master specification guidelines,
we requested a review of the original specs of the project completed
by the in-house design team before final approval. The buildings
plan would accommodate a variety of specialized research support
spaces, administrative offices, individual research staff offices,
conference rooms and an auditorium. Our research allowed us to
uncover potential problems in the design ahead of time in various
areas from the fuel hood elevations, electrical routing and the
UPS equipment, resulting in increased reliability, substantial
cost savings and an estimated 1 ½ months in design time.
Bristol-Myers Squibb Process Research
and Development Laboratory rendering |
In addition, the Syska Team served as the prime consultant for
the design of the BSL-3 BioSafety Laboratory. Working with the
owner, end-users and leading the architect and construction team
we designed the engineering driven facility, phasing in the design
and construction to allow for minimal disruption to the rest of
the building as it was also being built. All of the laboratories
were designed with a combination of fixed and adjustable case work,
bench top walk-in fume hoods and overhead services to allow for
future flexibility. Valued at an estimated $2 million dollars effort,
Bristol-Myers today has a new state-of-the art facility to continue
its valued research in the industry for cancer patients.
|
|
